Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | MARS1 | P56192 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 4/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933965 | 0.91 | KDM1A (0.44) | NTRK1CCKARKDM1A | |
| SCHEMBL4927600 | 0.91 | CCKAR (0.42) | NTRK1CCKARKDM1AMGLL | |
| SCHEMBL4927907 | 0.84 | KDM1A (0.46) | CCKARCYP3A4CYP2A6KDM1AGRM5 | |
| SCHEMBL14261654 | 0.84 | KDM1A (0.43) | CCKARCYP3A4CYP2A6KDM1AGRM5 | |
| SCHEMBL4929793 | 0.84 | MGLL (0.52) | NTRK1CCKARCYP3A4CYP2A6KDM1A | |
| SCHEMBL4929746 | 0.83 | MGLL (0.51) | MGLL | |
| SCHEMBL14261658 | 0.83 | CCKAR (0.41) | CCKARCYP3A4CYP2A6KDM1AGRM5 | |
| SCHEMBL4923262 | 0.82 | CYP3A4 (0.44) | CYP3A4CYP2A6MARS1MGLLSLC16A3 | |
| SCHEMBL4929745 | 0.82 | CYP3A4 (0.39) | CCKARCYP3A4CYP2A6KDM1AMARS1 | |
| SCHEMBL4925391 | 0.82 | KDM1A (0.44) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | NTRK1 2581/4885CCKAR 2046/4885PDE10A 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.